comparemela.com

Latest Breaking News On - Douglas tsao - Page 6 : comparemela.com

Coherus BioSciences, Inc (NASDAQ:CHRS) Q1 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Q1 2023 Earnings Call. Please be advised that today’s conference is being recorded.

United statesDenny lanfearMcdavid stilwellChris schottBalaji prasadJason gerberryTheresa lavalleeDavid stilwellMarek ciszewskiRobyn karnauskasPaul reiderMike nedelcovychNeulasta onproCoherus biosciencesDouglas tsaoRosh dias

Evolus, Inc (NASDAQ:EOLS) Q1 2023 Earnings Call Transcript

Operator: Greetings, and welcome to the Evolus First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

United statesUnited kingdomGreat britainRui avelarAnnabel samimySandra beaverLouise chenBalaji prasadDouglas tsaoMarc goodmanDavid moatazediDavid ericksonAmerican society for dermatologic surgery conferenceEvolus incCantor fitzgeraldEvolux program

Cerevel Therapeutics Holdings, Inc (NASDAQ:CERE) Q1 2023 Earnings Call Transcript

Operator: Good morning and welcome to Cerevel Therapeutics First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Matthew calistriMohit bansalGraig suvannavejhPaul matteisJessica fyeMark bodenraderRay sanchezJohn rengerMichael yeeMatt calistriMadhu kumarCharles duncanTony colesRon renaudJoseph thomeRaymond sanchez

H C Wainwright Sticks to Their Buy Rating for Argenx Se (ARGX)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Argenx Se (ARGX – Research Report) today and set a price target of $482.00.

Tim van hauwermeirenTorsten dreierDouglas tsaoResearch reportCabaletta bioStrong buy

H C Wainwright Keeps Their Hold Rating on Horizon Therapeutics (HZNP)

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Horizon Therapeutics (HZNP – Research Report). T.

Douglas tsaoMichael desjardinHorizon therapeutics plcHorizon therapeuticsResearch reportCabaletta bioRevance therapeuticsTechnical operationsTherapeutics plc

vimarsana © 2020. All Rights Reserved.